Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 and Isatuximab in Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gamgertamig in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2026; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07585760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07585760.